HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ISLR
immunoglobulin superfamily containing leucine rich repeat
Chromosome 15 · 15q24.1
NCBI Gene: 3671Ensembl: ENSG00000129009.14HGNC: HGNC:6133UniProt: A0A146E5L3
21PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
extracellular exosomecell adhesionextracellular regionplatelet alpha granule lumenneurodegenerative diseaseAbnormality of the skeletal systemHodgkins lymphomaneoplasm
✦AI Summary

ISLR (immunoglobulin superfamily containing leucine-rich repeat) is a secreted stromal protein with dual roles in tissue homeostasis and cancer progression. Primary function: ISLR functions as a cell adhesion molecule located in the extracellular region and platelet alpha granules 1. Mechanism: ISLR operates through multiple signaling pathways. In intestinal epithelium, stromal ISLR suppresses Hippo signaling and activates YAP to promote epithelial cell growth during regeneration 2. In cancer-associated fibroblasts (CAFs), ISLR promotes bone morphogenetic protein (BMP) signaling, contrasting with GREM1 which inhibits it 3. ISLR is regulated by BMP9/ALK1 signaling in cardiac progenitor cells and coordinates angiogenic responses 4. In gastric cancer, ISLR interacts with MGAT5 to promote malignant progression via epithelial-mesenchymal transition 5. Disease relevance: High ISLR expression correlates with poor survival in colorectal cancer but favorable survival when promoted in stromal cells 3. In triple-negative breast cancer, ISLR promotes immune evasion by stabilizing immunosuppressive niches via MIF/CD74 signaling 6. ISLR marks cancer-restraining CAFs in pancreatic cancer and maintains mesenchymal cell undifferentiation in adipose tissue 78. Clinical significance: ISLR represents a promising therapeutic target; AAV8-mediated ISLR delivery improved survival in hepatic metastasis models, while ISLR knockdown enhanced radiotherapy-induced anti-tumor immunity 36.

Sources cited
1
ISLR is an immunoglobulin superfamily protein with leucine-rich repeats located in the extracellular region; expressed in multiple tissues including retina
PMID: 10512678
2
ISLR in cancer-associated fibroblasts promotes BMP signaling; high ISLR expression associates with favorable survival in colorectal cancer; AAV8-ISLR delivery improves survival in hepatic metastasis
PMID: 33197448
3
Stromal ISLR is a secreted protein that suppresses epithelial Hippo signaling and activates YAP; essential for intestinal regeneration and colon tumorigenesis
PMID: 32128839
4
ISLR is highly expressed in gastric cancer and associated with poor prognosis; interacts with MGAT5 to promote malignant progression and epithelial-mesenchymal transition
PMID: 37427332
5
ISLR is a regulated target of BMP9/ALK1 signaling in cardiac progenitor cells; involved in pro-angiogenic secretome responses
PMID: 39430425
6
ISLR promotes immune evasion in triple-negative breast cancer via MIF/CD74 signaling pathway; ISLR knockdown enhances radiotherapy-induced anti-tumor immunity
PMID: 40517736
7
ISLR marks cancer-restraining CAFs in pancreatic cancer that suppress tumor progression
PMID: 31439548
8
ISLR/Meflin marks adipose stem and progenitor cells; maintains undifferentiated status and suppresses white adipose tissue fibrosis
PMID: 39136356
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.44Moderate
Abnormality of the skeletal systemOpen Targets
0.36Weak
Hodgkins lymphomaOpen Targets
0.31Weak
neoplasmOpen Targets
0.11Weak
non-small cell lung carcinomaOpen Targets
0.09Suggestive
colorectal carcinomaOpen Targets
0.08Suggestive
osteosarcomaOpen Targets
0.08Suggestive
gastric cancerOpen Targets
0.06Suggestive
uterine fibroidOpen Targets
0.04Suggestive
Uterine leiomyomaOpen Targets
0.04Suggestive
Testicular regression syndromeOpen Targets
0.04Suggestive
cancerOpen Targets
0.04Suggestive
Down syndromeOpen Targets
0.04Suggestive
46,XX ovotesticular disorder of sex developmentOpen Targets
0.04Suggestive
metaphyseal dysplasia, Braun-Tinschert typeOpen Targets
0.04Suggestive
esophageal squamous cell carcinomaOpen Targets
0.04Suggestive
Weismann-Netter syndromeOpen Targets
0.04Suggestive
46,XY complete gonadal dysgenesisOpen Targets
0.04Suggestive
Hypocalcemic vitamin D-resistant ricketsOpen Targets
0.04Suggestive
testicular agenesisOpen Targets
0.03Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
SIGLEC14Shared pathway100%SIGLEC11Shared pathway100%MUC16Shared pathway100%SIGLEC12Shared pathway100%SIGLEC8Shared pathway100%SIGLEC7Shared pathway100%
Tissue Expression6 tissues
Ovary
100%
Heart
32%
Lung
15%
Liver
5%
Brain
5%
Bone Marrow
0%
Gene Interaction Network
Click a node to explore
ISLRSIGLEC14SIGLEC11MUC16SIGLEC12SIGLEC8SIGLEC7
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt O14498
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.75LoF Tolerant
pLIⓘ
0.38Tolerant
Observed/Expected LoF0.40 [0.23–0.75]
RankingsWhere ISLR stands among ~20K protein-coding genes
  • #13,935of 20,598
    Most Researched21
  • #5,892of 17,882
    Most Constrained (LOEUF)0.75
Genes detectedISLR
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
The Balance of Stromal BMP Signaling Mediated by GREM1 and ISLR Drives Colorectal Carcinogenesis.
PMID: 33197448
Gastroenterology · 2021
1.00
2
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis.
PMID: 31439548
Cancer Res · 2019
0.90
3
Human and mouse ISLR (immunoglobulin superfamily containing leucine-rich repeat) genes: genomic structure and tissue expression.
PMID: 10512678
Genomics · 1999
0.80
4
ALK1 Signaling in Human Cardiac Progenitor Cells Promotes a Pro-angiogenic Secretome.
PMID: 39430425
J Cell Signal · 2024
0.70
5
ISLR interacts with MGAT5 to promote the malignant progression of human gastric cancer AGS cells.
PMID: 37427332
Iran J Basic Med Sci · 2023
0.60